These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 28247415)
1. Novel Monoclonal Antibodies Recognizing Human Prostate-Specific Membrane Antigen (PSMA) as Research and Theranostic Tools. Nováková Z; Foss CA; Copeland BT; Morath V; Baranová P; Havlínová B; Skerra A; Pomper MG; Barinka C Prostate; 2017 May; 77(7):749-764. PubMed ID: 28247415 [TBL] [Abstract][Full Text] [Related]
2. Engineered Fragments of the PSMA-Specific 5D3 Antibody and Their Functional Characterization. Novakova Z; Belousova N; Foss CA; Havlinova B; Gresova M; Das G; Lisok A; Prada A; Barinkova M; Hubalek M; Pomper MG; Barinka C Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32932591 [TBL] [Abstract][Full Text] [Related]
3. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535 [TBL] [Abstract][Full Text] [Related]
4. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Wolf P; Freudenberg N; Bühler P; Alt K; Schultze-Seemann W; Wetterauer U; Elsässer-Beile U Prostate; 2010 Apr; 70(5):562-9. PubMed ID: 19938014 [TBL] [Abstract][Full Text] [Related]
5. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen. Huang X; Bennett M; Thorpe PE Prostate; 2004 Sep; 61(1):1-11. PubMed ID: 15287089 [TBL] [Abstract][Full Text] [Related]
6. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Smith-Jones PM; Vallabahajosula S; Goldsmith SJ; Navarro V; Hunter CJ; Bastidas D; Bander NH Cancer Res; 2000 Sep; 60(18):5237-43. PubMed ID: 11016653 [TBL] [Abstract][Full Text] [Related]
7. Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy. Huang CT; Guo X; Bařinka C; Lupold SE; Pomper MG; Gabrielson K; Raman V; Artemov D; Hapuarachchige S Mol Pharm; 2020 Sep; 17(9):3392-3402. PubMed ID: 32803984 [TBL] [Abstract][Full Text] [Related]
8. Isolation and characterization of monoclonal antibodies specific for protein conformational epitopes present in prostate-specific membrane antigen (PSMA). Tino WT; Huber MJ; Lake TP; Greene TG; Murphy GP; Holmes EH Hybridoma; 2000 Jun; 19(3):249-57. PubMed ID: 10952413 [TBL] [Abstract][Full Text] [Related]
10. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. Smith-Jones PM; Vallabhajosula S; Navarro V; Bastidas D; Goldsmith SJ; Bander NH J Nucl Med; 2003 Apr; 44(4):610-7. PubMed ID: 12679407 [TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen. Wang X; Ma D; Olson WC; Heston WD Mol Cancer Ther; 2011 Sep; 10(9):1728-39. PubMed ID: 21750220 [TBL] [Abstract][Full Text] [Related]
12. The therapeutic potential of a novel PSMA antibody and its IL-2 conjugate in prostate cancer. Sugimoto Y; Hirota M; Yoshikawa K; Sumitomo M; Nakamura K; Ueda R; Niwa R; Suzawa T; Yamasaki M; Shitara K; Kato T; Nakamura K Anticancer Res; 2014 Jan; 34(1):89-97. PubMed ID: 24403448 [TBL] [Abstract][Full Text] [Related]
13. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Ma D; Hopf CE; Malewicz AD; Donovan GP; Senter PD; Goeckeler WF; Maddon PJ; Olson WC Clin Cancer Res; 2006 Apr; 12(8):2591-6. PubMed ID: 16638870 [TBL] [Abstract][Full Text] [Related]
14. High-resolution animal PET imaging of prostate cancer xenografts with three different 64Cu-labeled antibodies against native cell-adherent PSMA. Alt K; Wiehr S; Ehrlichmann W; Reischl G; Wolf P; Pichler BJ; Elsässer-Beile U; Bühler P Prostate; 2010 Sep; 70(13):1413-21. PubMed ID: 20687214 [TBL] [Abstract][Full Text] [Related]
15. Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer. Evazalipour M; D'Huyvetter M; Tehrani BS; Abolhassani M; Omidfar K; Abdoli S; Arezumand R; Morovvati H; Lahoutte T; Muyldermans S; Devoogdt N Contrast Media Mol Imaging; 2014; 9(3):211-20. PubMed ID: 24700748 [TBL] [Abstract][Full Text] [Related]
16. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Bander NH; Nanus DM; Milowsky MI; Kostakoglu L; Vallabahajosula S; Goldsmith SJ Semin Oncol; 2003 Oct; 30(5):667-76. PubMed ID: 14571414 [TBL] [Abstract][Full Text] [Related]
17. Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts. DiPippo VA; Olson WC; Nguyen HM; Brown LG; Vessella RL; Corey E Prostate; 2015 Feb; 75(3):303-13. PubMed ID: 25327986 [TBL] [Abstract][Full Text] [Related]
18. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen. Li Y; Tian Z; Rizvi SM; Bander NH; Allen BJ Prostate Cancer Prostatic Dis; 2002; 5(1):36-46. PubMed ID: 15195129 [TBL] [Abstract][Full Text] [Related]
19. A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer. Frigerio B; Fracasso G; Luison E; Cingarlini S; Mortarino M; Coliva A; Seregni E; Bombardieri E; Zuccolotto G; Rosato A; Colombatti M; Canevari S; Figini M Eur J Cancer; 2013 Jun; 49(9):2223-32. PubMed ID: 23433847 [TBL] [Abstract][Full Text] [Related]